Studies related to IGF-1 and Melatonin

A Randomized Controlled Trial Of Oral Melatonin Supplementation And Breast Cancer Biomarkers

Effect None
Trial Design Double blind
Trial Length n/a
Number of Subjects 86
Sex n/a
Notes for this study:
3mg of melatonin 30 minutes before sleep in postmenopausal breast cancer survivors over 4 months failed to note changes in hormonal breast cancer markers (including IGFBP-1)